Immunic (IMUX) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Immunic (IMUX) has outperformed Unicycive Therapeutics (UNCY) over the past year, losing 11.0% versus a loss of 13.1%. Over five years, UNCY leads with a -84.9% price change compared with -90.6% for IMUX. Unicycive Therapeutics is the larger company by market cap ($112.6 million vs $111.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | UNCY |
|---|---|---|
| Share price | $8.19 | $4.11 |
| Market cap | $111.75M | $112.59M |
| 1-day change | +8.33% | +0.98% |
| YTD return | +53.37% | -28.77% |
| 1-year return | -10.98% | -13.11% |
| 5-year return | -90.55% | -84.91% |
| Forward P/E | — | 2.44 |
| EPS (TTM) | $-4.17 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.43 | $8.74 |
| 52-week low | $5.06 | $3.93 |
| Distance from 52-week high | -53.01% | -52.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +426.13% | +591.00% |
| Average volume | 284.68K | 834.69K |
| Shares outstanding | 13.64M | 27.39M |
| Employees | 100 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
IMUX vs UNCY FAQ
Which is bigger, Immunic or Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $112.59M compared with $111.75M for Immunic (IMUX).
Which stock has performed better over the past year, IMUX or UNCY?
IMUX returned -10.98% over the past 12 months, compared with -13.11% for UNCY (price return, excluding dividends). Past performance does not predict future results.
Are Immunic and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.